162 related articles for article (PubMed ID: 2105731)
1. Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin.
Columbo M; Galeone D; Guidi G; Kagey-Sobotka A; Lichtenstein LM; Pettit GR; Marone G
Biochem Pharmacol; 1990 Jan; 39(2):285-91. PubMed ID: 2105731
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the release of histamine and arachidonic acid metabolites from human basophils and mast cells by auranofin.
Marone G; Columbo M; Galeone D; Guidi G; Kagey-Sobotka A; Lichtenstein LM
Agents Actions; 1986 Apr; 18(1-2):100-2. PubMed ID: 2425566
[TBL] [Abstract][Full Text] [Related]
3. Nimesulide, a sulfonanilide nonsteroidal anti-inflammatory drug, inhibits mediator release from human basophils and mast cells.
Casolaro V; Meliota S; Marino O; Patella V; de Paulis A; Guidi G; Marone G
J Pharmacol Exp Ther; 1993 Dec; 267(3):1375-85. PubMed ID: 7505332
[TBL] [Abstract][Full Text] [Related]
4. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells.
de Paulis A; Cirillo R; Ciccarelli A; Condorelli M; Marone G
J Immunol; 1991 Apr; 146(7):2374-81. PubMed ID: 1706398
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin.
Cirillo R; Triggiani M; Siri L; Ciccarelli A; Pettit GR; Condorelli M; Marone G
J Immunol; 1990 May; 144(10):3891-7. PubMed ID: 1692065
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin.
Marone G; Columbo M; Triggiani M; Cirillo R; Genovese A; Formisano S
Biochem Pharmacol; 1987 Jan; 36(1):13-20. PubMed ID: 2432900
[TBL] [Abstract][Full Text] [Related]
7. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils.
Columbo M; Horowitz EM; Botana LM; MacGlashan DW; Bochner BS; Gillis S; Zsebo KM; Galli SJ; Lichtenstein LM
J Immunol; 1992 Jul; 149(2):599-608. PubMed ID: 1378071
[TBL] [Abstract][Full Text] [Related]
8. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.
Zuberbier T; Chong SU; Grunow K; Guhl S; Welker P; Grassberger M; Henz BM
J Allergy Clin Immunol; 2001 Aug; 108(2):275-80. PubMed ID: 11496246
[TBL] [Abstract][Full Text] [Related]
9. Physiological concentrations of zinc inhibit the release of histamine from human basophils and lung mast cells.
Marone G; Columbo M; de Paulis A; Cirillo R; Giugliano R; Condorelli M
Agents Actions; 1986 Apr; 18(1-2):103-6. PubMed ID: 2425567
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin A inhibits the release of histamine and peptide leukotriene C4 from human lung mast cells.
Marone G; Triggiani M; Cirillo R; Giacummo A; Siri L; Condorelli M
Ric Clin Lab; 1988; 18(1):53-9. PubMed ID: 2453912
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the anti-inflammatory effect of FK-506 on human mast cells.
de Paulis A; Cirillo R; Ciccarelli A; de Crescenzo G; Oriente A; Marone G
J Immunol; 1991 Dec; 147(12):4278-85. PubMed ID: 1721644
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949.
Conroy MC; Kennedy JA; Chestnut JC; Wright CD; Adolphson RL; Thueson DO
J Allergy Clin Immunol; 1990 Dec; 86(6 Pt 1):902-8. PubMed ID: 1702129
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of activation of human mast cells and basophils by general anesthetic drugs.
Marone G; Stellato C; Mastronardi P; Mazzarella B
Ann Fr Anesth Reanim; 1993; 12(2):116-25. PubMed ID: 7690200
[TBL] [Abstract][Full Text] [Related]
14. Contrast media are incomplete secretagogues acting on human basophils and mast cells isolated from heart and lung, but not skin tissue.
Genovese A; Stellato C; Patella V; Lamparter-Schummert B; de Crescenzo G; Adt M; Marone G
Int J Clin Lab Res; 1996; 26(3):192-8. PubMed ID: 8905451
[TBL] [Abstract][Full Text] [Related]
15. Purified human basophils do not generate LTB4.
Warner JA; Freeland HS; MacGlashan DW; Lichtenstein LM; Peters SP
Biochem Pharmacol; 1987 Oct; 36(19):3195-9. PubMed ID: 2444228
[TBL] [Abstract][Full Text] [Related]
16. The antineoplastic bryostatins affect human basophils and mast cells differently.
Patella V; Casolaro V; Ciccarelli A; Pettit GR; Columbo M; Marone G
Blood; 1995 Mar; 85(5):1272-81. PubMed ID: 7532037
[TBL] [Abstract][Full Text] [Related]
17. Protein Fv produced during vital hepatitis is a novel activator of human basophils and mast cells.
Patella V; Bouvet JP; Marone G
J Immunol; 1993 Nov; 151(10):5685-98. PubMed ID: 7693815
[TBL] [Abstract][Full Text] [Related]
18. Auranofin, an oral chrysotherapeutic agent, inhibits histamine release from human basophils.
Takaishi T; Morita Y; Kudo K; Miyamoto T
J Allergy Clin Immunol; 1984 Sep; 74(3 Pt 1):296-301. PubMed ID: 6206106
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous effects of protamine on human mast cells and basophils.
Patella V; Ciccarelli A; Lamparter-Schummert B; de Paulis A; Adt M; Marone G
Br J Anaesth; 1997 Jun; 78(6):724-30. PubMed ID: 9215027
[TBL] [Abstract][Full Text] [Related]
20. Protein L. A bacterial Ig-binding protein that activates human basophils and mast cells.
Patella V; Casolaro V; Björck L; Marone G
J Immunol; 1990 Nov; 145(9):3054-61. PubMed ID: 1698870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
